COPD News

SAN DIEGO — After bronchoscopic lung volume reduction, or BLVR, patients with COPD and alpha-1 antitrypsin deficiency had better lung function, according to a poster at the American Thoracic Society International Conference.

The FDA has approved the phosphodiesterase enzyme 3 and 4 inhibitor ensifentrine, now named Ohtuvayre, for treating adults with COPD, according to a manufacturer-issued press release.

COPD appeared more frequently and was more likely in an LGBTQ+ population vs. a heterosexual and/or cisgender population, according to research published in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation.

We are currently experiencing a renaissance in the treatment landscape for respiratory disease, but we can do better.

SAN DIEGO — An inhaler with beclomethasone dipropionate, formoterol fumarate and glycopyrronium lowered lung hyperinflation in patients with COPD, according to research presented at the American Thoracic Society International Conference.

The FDA is expected to make a decision on ensifentrine to treat patients with COPD by June 26.

Use of race-neutral/race-free equations to find FEV1 revealed that some Black smokers had more severe COPD than previously found with race-specific equations, according to results published in CHEST.

During a Midwest Comparative Effectiveness Public Advisory Council public meeting, 11 of 15 members believed current evidence was adequate in showing the net health benefit of ensifentrine plus maintenance therapy.

SAN DIEGO — More than 75% of individuals who underwent lung cancer screening without a reported history of COPD had airways disease, according to research presented at the American Thoracic Society International Conference.

SAN DIEGO — Lung abnormalities appeared more frequently on CT scans from young current smokers vs. never smokers, according to research presented at the American Thoracic Society International Conference.